Rokit Healthcare
Pioneering 4d Bioprinting

With the general increase in life expectancy across the globe and the increasing scarcity of financial resources dedicated toward centralized healthcare systems, the need for innovative, personalized medicine is higher than ever. Seoul-based ROKIT Healthcare is a global healthcare company pioneering in offering the safest and most effective autologous organ regeneration platforms using its proprietary 4D bioprinting technologies across all types of applicable age-related diseases. Through a convergence of know-how's and innovation in the areas of bioprinting, autologous stem cell treatments, surgical medicine, and regulatory affairs, ROKIT Healthcare believes that supplying customized organ regeneration platform services will drastically change the way one trusts and manages the health of its body.

ROKIT Healthcare has brought a revolutionary transition in bioprinting industry 'from bench to clinic' by providing bioprinters that realize researchers’ and healthcare professionals’ vision, which is ultimately the customized, in-hospital biofabrication of human tissues. “We endeavor to change the world by providing the safest and effective organ regeneration services with our specialized expertise in regenerative medicine,” states SeokHwan You, founder and CEO of ROKIT Healthcare. ROKIT Healthcare provides a 4D bioprinting platform, Dr. INVIVO which is known for introducing some of the world’s first built-in revolutions to bioprinter devices, including cleanbench system with.

disinfection and filtered air flow capabilities. Currently, Dr. INVIVO portfolio principally includes Dr. INVIVO 4D2 and Dr. INVIVO 4D6.

Dr. INVIVO 4D2 is the first clean-chamber bioprinter pioneering the way for effective, on-demand biofabrication of human tissue models and implants. It is capable of printing freeform cell suspensions, hydrogels, thermoplastic filaments, pastes, and other composite materials, enabling both hard and soft tissue engineering. Dr. INVIVO 4D6 is a bioreactor-based bioprinting platform with a built-in cell incubator and low-temperature plasma sterilizer as the first of its kind. It is designed and built with the vision of in-hospital manufacturing and offers a controlled cellular environment in aseptic conditions in combination with the complex biofabrication technologies of six rotary printheads.

The company also provides a patient-customized Skin Regeneration Platform that treats various range of skin wounds such as scar, burn, and diabetic foot ulcer. For the first time in the world, by combining tissue engineering and 3D bioprinting technology ROKIT Healthcare provides novel treatment based on autologous adipose tissue derived SVF cells and whole native extracellular matrix and other FDA approved substances within minimal manipulation boundary. In addition to being a bioprinter manufacturer, ROKIT Healthcare works as a medical contractor that partners with state agencies, biotech firms, and academic research centers to develop applications for bioprinting technology in the hospital operating room.

Founded in 2012 and active in more than 50 countries, the company is advancing the scientific and healthcare revolution in regenerative medicine by providing on-demand human tissue manufacturing solutions in vivo and in vitro. From ROKIT Healthcare’s perspective, bioprinting sets the base for the personalized therapy solutions they are planning to introduce to global hospitals, from patient-specific skin, cartilage, and bone regeneration to heart and retina patch biofabrication solutions. ROKIT Healthcare believes that bioprinting must come together with other preventive medicine and diagnostic technologies, digitalization, and healthcare management strategies to be truly effective at the level of patient outcomes. ROKIT Healthcare thus seeks to address regenerative medicine and healthcare from a much wider vantage point, with bioprinting as an important theme.